Sophia Tsouros
Ottawa Hospital Research Institute
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Sophia Tsouros.
Evidence-based Complementary and Alternative Medicine | 2012
Andrea D Furlan; F Yazdi; Alexander Tsertsvadze; Anita Gross; Maurits Van Tulder; Lina Santaguida; Joel Gagnier; Carlo Ammendolia; Trish Dryden; Steve Doucette; Becky Skidmore; Raymond Daniel; Thomas Ostermann; Sophia Tsouros
Background. Back pain is a common problem and a major cause of disability and health care utilization. Purpose. To evaluate the efficacy, harms, and costs of the most common CAM treatments (acupuncture, massage, spinal manipulation, and mobilization) for neck/low-back pain. Data Sources. Records without language restriction from various databases up to February 2010. Data Extraction. The efficacy outcomes of interest were pain intensity and disability. Data Synthesis. Reports of 147 randomized trials and 5 nonrandomized studies were included. CAM treatments were more effective in reducing pain and disability compared to no treatment, physical therapy (exercise and/or electrotherapy) or usual care immediately or at short-term follow-up. Trials that applied sham-acupuncture tended towards statistically nonsignificant results. In several studies, acupuncture caused bleeding on the site of application, and manipulation and massage caused pain episodes of mild and transient nature. Conclusions. CAM treatments were significantly more efficacious than no treatment, placebo, physical therapy, or usual care in reducing pain immediately or at short-term after treatment. CAM therapies did not significantly reduce disability compared to sham. None of the CAM treatments was shown systematically as superior to one another. More efforts are needed to improve the conduct and reporting of studies of CAM treatments.
Journal of Clinical Epidemiology | 2011
Tatyana Shamliyan; Robert L. Kane; Mohammed T. Ansari; Gowri Raman; Nancy D Berkman; Mark D Grant; Gail Janes; Margaret Maglione; David Moher; Mona Nasser; Karen A. Robinson; Jodi B. Segal; Sophia Tsouros
OBJECTIVE To develop two checklists for the quality of observational studies of incidence or risk factors of diseases. STUDY DESIGN AND SETTING Initial development of the checklists was based on a systematic literature review. The checklists were refined after pilot trials of validity and reliability were conducted by seven experts, who tested the checklists on 10 articles. RESULTS The checklist for studies of incidence or prevalence of chronic disease had six criteria for external validity and five for internal validity. The checklist for risk factor studies had six criteria for external validity, 13 criteria for internal validity, and two aspects of causality. A Microsoft Access database produced automated standardized reports about external and internal validities. Pilot testing demonstrated face and content validities and discrimination of reporting vs. methodological qualities. Interrater agreement was poor. The experts suggested future reliability testing of the checklists in systematic reviews with preplanned protocols, a priori consensus about research-specific quality criteria, and training of the reviewers. CONCLUSION We propose transparent and standardized quality assessment criteria of observational studies using the developed checklists. Future testing of the checklists in systematic reviews is necessary to develop reliable tools that can be used with confidence.
BMJ | 2014
Andrea C. Tricco; Huda Ashoor; Jesmin Antony; Joseph Beyene; Areti Angeliki Veroniki; Wanrudee Isaranuwatchai; Alana Harrington; Charlotte Wilson; Sophia Tsouros; Charlene Soobiah; Catherine H Yu; Brian Hutton; Jeffrey S. Hoch; Brenda R. Hemmelgarn; David Moher; Sumit R. Majumdar; Sharon E. Straus
Objective To examine the safety, effectiveness, and cost effectiveness of long acting insulin for type 1 diabetes. Design Systematic review and network meta-analysis. Data sources Medline, Cochrane Central Register of Controlled Trials, Embase, and grey literature were searched through January 2013. Study selection Randomized controlled trials or non-randomized studies of long acting (glargine, detemir) and intermediate acting (neutral protamine Hagedorn (NPH), lente) insulin for adults with type 1 diabetes were included. Results 39 studies (27 randomized controlled trials including 7496 patients) were included after screening of 6501 titles/abstracts and 190 full text articles. Glargine once daily, detemir once daily, and detemir once/twice daily significantly reduced hemoglobin A1c compared with NPH once daily in network meta-analysis (26 randomized controlled trials, mean difference −0.39%, 95% confidence interval −0.59% to −0.19%; −0.26%, −0.48% to −0.03%; and −0.36%, −0.65% to −0.08%; respectively). Differences in network meta-analysis were observed between long acting and intermediate acting insulin for severe hypoglycemia (16 randomized controlled trials; detemir once/twice daily versus NPH once/twice daily: odds ratio 0.62, 95% confidence interval 0.42 to 0.91) and weight gain (13 randomized controlled trials; detemir once daily versus NPH once/twice daily: mean difference 4.04 kg, 3.06 to 5.02 kg; detemir once/twice daily versus NPH once daily: −5.51 kg, −6.56 to −4.46 kg; glargine once daily versus NPH once daily: −5.14 kg, −6.07 to −4.21). Compared with NPH, detemir was less costly and more effective in 3/14 cost effectiveness analyses and glargine was less costly and more effective in 2/8 cost effectiveness analyses. The remaining cost effectiveness analyses found that detemir and glargine were more costly but more effective than NPH. Glargine was not cost effective compared with detemir in 2/2 cost effectiveness analyses. Conclusions Long acting insulin analogs are probably superior to intermediate acting insulin analogs, although the difference is small for hemoglobin A1c. Patients and their physicians should tailor their choice of insulin according to preference, cost, and accessibility. Systematic review registration PROSPERO CRD42013003610.
Clinical Biochemistry | 2011
Evelin Loit; Andrea C. Tricco; Sophia Tsouros; Margaret Sears; Mohammed T Ansari; Ronald A. Booth
OBJECTIVES Low thiopurine S-methyltransferase (TPMT) enzyme activity is associated with increased thiopurine drug toxicity, particularly myelotoxicity. Pre-analytic and analytic variables for TPMT genotype and phenotype (enzyme activity) testing were reviewed. DESIGN AND METHODS A systematic literature review was performed, and diagnostic laboratories were surveyed. RESULTS Thirty-five studies reported relevant data for pre-analytic variables (patient age, gender, race, hematocrit, co-morbidity, co-administered drugs and specimen stability) and thirty-three for analytic variables (accuracy, reproducibility). TPMT is stable in blood when stored for up to 7 days at room temperature, and 3 months at -30°C. Pre-analytic patient variables do not affect TPMT activity. Fifteen drugs studied to date exerted no clinically significant effects in vivo. Enzymatic assay is the preferred technique. Radiochemical and HPLC techniques had intra- and inter-assay coefficients of variation (CVs) below 10%. CONCLUSION TPMT is a stable enzyme, and its assay is not affected by age, gender, race or co-morbidity.
Evidence report/technology assessment | 2010
Andrea D. Furlan; Fatemeh Yazdi; Alexander Tsertsvadze; Anita Gross; Maurits W. van Tulder; Lina Santaguida; Dan Cherkin; Joel Gagnier; Carlo Ammendolia; Mohammed T. Ansari; Thomas Ostermann; Trish Dryden; Steve Doucette; Becky Skidmore; Raymond Daniel; Sophia Tsouros; Laura Weeks; James Galipeau
Evidence report/technology assessment | 2012
Charles Hui; Gina Neto; Alexander Tsertsvadze; Fatemeh Yazdi; Andrea C. Tricco; Sophia Tsouros; Becky Skidmore; Raymond Daniel
Systematic Reviews | 2013
Nadera Ahmadzai; Sydne Newberry; Margaret Maglione; Alexander Tsertsvadze; Mohammed T Ansari; Susanne Hempel; Aneesa Motala; Sophia Tsouros; Jennifer Schneider Chafen; Roberta Shanman; David Moher; Paul G. Shekelle
Archive | 2010
Andrea D Furlan; Fatemeh Yazdi; Alexander Tsertsvadze; Anita Gross; Maurits Van Tulder; Lina Santaguida; Dan Cherkin; Joel Gagnier; Carlo Ammendolia; Mohammed T Ansari; Thomas Ostermann; Trish Dryden; Steve Doucette; Becky Skidmore; Raymond Daniel; Sophia Tsouros; Laura Weeks; James Galipeau
Evidence report/technology assessment | 2010
Ronald A. Booth; Mohammed T. Ansari; Andrea C. Tricco; Evelin Loit; Laura Weeks; Steve Doucette; Becky Skidmore; Jeffrey S. Hoch; Sophia Tsouros; Margaret Sears; Richmond Sy; Jacob Karsh; Suja Mani; James Galipeau; Alexander Yurkiewich; Raymond Daniel; Alexander Tsertsvadze; Fatemeh Yazdi
American Journal of Public Health Research | 2013
Tatyana Shamliyan; Mohammed T. Ansari; Gowri Raman; Nancy D Berkman; Mark D Grant; Gail Janes; Margaret Maglione; David Moher; Mona Nasser; Karen A. Robinson; Jodi B. Segal; Sophia Tsouros